Health
Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC – MedPage Today
More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab.
Neoadjuvant combination immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) produced a significant clinical benefit for patients with operable stage I-III non-small cell lung cancer (NSCLC), researchers reported.
The phase II NEOSTAR study randomly assigned 44 patients with operable NSCLC to neoadjuvant nivolumab with or without ipilimumab followed by surgery. Among those, 38% of patients that received the combination achieved major pathological response (MPR) — defined as 10% or less…
-
Business21 hours agoWarning! These ASX 200 shares were just downgraded
-
Business14 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Noosa News11 hours agoAFL live updates: Gold Coast vs Essendon – blog, scores and stats
-
Noosa News10 hours agoTwo-time Archibald Prize-winning painter William Robinson has died, aged 89